Embla Medical hf.
OSSUY
Other OTC3.82
USD
- -
- -
Embla Medical hf.
OSSUY
(Other OTC)
Recent
price
3.82
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Embla Medical hf. (Nasdaq Copenhagen: EMBLA; OTC: OSSUY), formerly Össur hf., develops, manufactures and markets non-invasive orthopedic products that improve mobility for people with limb loss or difference, neurological conditions, injuries and musculoskeletal disorders; it operates through three segments including Prosthetics and Neuro Orthotics, which offers mechanical lower- and upper-limb prosthetic components as well as bionic microprocessor-controlled feet, knees, hands, fingers and neuro orthotic joints; Bracing and Supports, which provides spinal, hip, knee, foot, ankle and hand support devices alongside injury solutions for fractures, post-operative recovery and ligament injuries; and Patient Care, which delivers prosthetics and orthotics for neurological, gait and musculoskeletal conditions through its ForMotion network of clinics. The company, founded in 1971 and headquartered in Reykjavik, Iceland, serves orthopedic clinics, hospitals, surgery centers, rehabilitation specialists and patients worldwide via direct sales and distributors across the Americas, Europe, Middle East, Africa and Asia-Pacific; its portfolio includes leading brands such as Össur for prosthetics and bracing solutions, Fior & Gentz for innovative lower-limb neuro orthotics, and College Park for custom lower-limb prosthetics tailored to diverse activity levels. Embla Medical is a subsidiary of William Demant Invest A/S and pursues its Growth'27 strategy focused on patient reach, innovative solutions and orthotic & prosthetic value creation in chronic mobility markets alongside a simplified bracing portfolio. In April 2024, the company changed its name from Össur hf. to Embla Medical hf. and acquired Fior & Gentz to expand into neuro orthotics; in July 2025 it signed and closed in August 2025 a 51% majority stake investment in Streifeneder ortho.production GmbH, a developer of prosthetic components, orthotic solutions and orthopedic materials with EUR 25 million in 2024 sales (70% from prosthetics), funded by issuing 2,805,135 new shares at DKK 33.26 each for DKK 93 million (EUR 12.5 million) with a two-year seller lock-up; these moves support organic sales growth of 6% in 2024 to USD 855 million and reiterated 2025 guidance of 5-8% organic growth with 20-21% EBITDA margin before special items, driven by double-digit expansion in Prosthetics & Neuro Orthotics including recently launched innovations.
Embla Medical hf. (OSSUY) Q1 2026 Earnings Call Transcript
Embla Medical hf. (OSSUY) Q4 2025 Earnings Call Transcript
Embla Medical hf. (OSSUY) Q3 2025 Earnings Call Transcript
Embla Medical hf: Embla Medical signs agreement to invest in a majority share in Streifeneder ortho.production GmbH